NCT01712256View on ClinicalTrials.gov

Re-boosting of HIV-1 Infected Subjects With Vacc-4x

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
HIV-1 Infection
Interventions
BIOLOGICAL

Vacc-4x

Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

Trial Locations (10)

12157

EIPMED - Gesellschaft fűr epidemiologische und klinische Forschung in der Medizin mbH Rubensstrasse 125, Berlin

20099

ifi - Studien und Projekte GmbH, an der Asklepios-Klinik St. George, Hamburg

20127

Istituto San Raffaele, Milan

20246

Universitätsklinikum Hamburg Eppendorf, Hamburg

53127

Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I; Immunologische Ambulanz, Siegmund-Freud-Str. 25, Bonn

90035

UCLA CARE Center, Los Angeles

95817

UC Davis Medical Center, Sacramento

08916

Hospital Germans Trias i Pujol, Badalona

08907

Unidad de VIH, Hospital de Bellvitge, Calle Feixa Llarga s/n, Hospitalet de Llobregat., Barcelona

SE1 7EH

Harrison Wing St Thomas' Hospital, London

All Listed Sponsors
lead

Bionor Immuno AS

INDUSTRY

NCT01712256 - Re-boosting of HIV-1 Infected Subjects With Vacc-4x | Biotech Hunter | Biotech Hunter